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American Heart Association/American Stroke Association expert
consensus guidelines recommend consideration of cardiac stress
testing to screen for occult coronary heart disease (CHD) among
patients with ischemic stroke/TIA who have a high-risk Framingham
Cardiac Risk Score (FCRS). Whether this guideline is being imple-
mented in routine clinical practice, and the association of its imple-
mentation with mortality, is less clear.
Methods
Study participants were Veterans with stroke/TIA (n = 11,306)
during fiscal year 2011 who presented to a VA Emergency Department or who were admitted.
Patients were excluded (n = 6,915) based on prior CHD/angina/chest pain history, receipt of
cardiac stress testing within 18 months prior to cerebrovascular event, death within 90 days of
discharge, discharge to hospice, transfer to a non-VA acute care facility, or missing/unknown
race. FCRS ≥20% was classified as high risk for CHD. ICD-9 and Common Procedural
Terminology codes were used to identify receipt of any cardiac stress testing.
Results
Among 4,391 eligible patients, 62.8% (n = 2,759) had FCRS ≥20%. Cardiac stress testing
was performed infrequently and in similar proportion among high-risk (4.5% [123/2,759]) vs
low/intermediate-risk (4.4% [72/1,632]) patients (adjusted odds ratio [aOR] 0.77, 95%
confidence interval [CI] 0.54–1.10). Receipt of stress testing was not associated with reduced
1-year mortality (aOR 0.59, CI 0.26–1.30).
Conclusions
In this observational cohort study of patients with cerebrovascular disease, cardiac screening was
relatively uncommon and was not associated with 1-year mortality. Additional work is needed to
understand the utility of CHD screening among high-risk patients with cerebrovascular disease.
Neurology Service (JJS), Clinical Epidemiology Research Center (CERC) (JJS, JC), and Medical Service (JC, FJ), VA Connecticut Healthcare System, West Haven; Department of Neurology
(JJS), Center for Neuroepidemiological and Clinical Research (JJS), and Department of Internal Medicine (JJS, JC, JF, FJ), Yale School of Medicine, New Haven, CT; VA Health Services
Research and Development (HSR&D) Center for Health Information and Communication (CHIC) (FB, LJM, JF, LSW, DMB) and theHSR&D StrokeQuality Enhancement Research Initiative
(QUERI) (FB, LJM, JF, LSW, DMB), Richard L. Roudebush VAMedical Center, Indianapolis; Departments of Biostatistics (FB, ZY), Internal Medicine (LJM, DMB), and Neurology (LSW, DMB),
Indiana University School of Medicine, Indianapolis; Department of Neurology (EMC), VA Greater Los Angeles Healthcare System and David Geffen School of Medicine, University of
California, Los Angeles; College of Health and Human Services (GA), Purdue University School of Nursing; Department of Pharmacy Practice (AJZ), Purdue University College of
Pharmacy, West Lafayette, IN; Department of Epidemiology and Biostatistics (MJR), Michigan State University, East Lansing; and Regenstrief Institute (LSW, DMB), Indianapolis, IN.
Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at
Neurology.org/cp.
The Article Processing Charge was funded by Department of Veterans Affairs (VA), Health Services Research and Development.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading
and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
192 Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Ischemic stroke and coronary heart disease (CHD) share many
vascular risk factors (e.g., hypertension),1,2 with 20%–30% of
stroke patients having symptomatic CHD and another 40%
having silent cardiac ischemia.3 Although cardiac evaluation
among patients with acute or subacute stroke largely focuses on
discerning whether an event was caused by a cardioembolic
source,4 the American Heart Association/American Stroke
Association (AHA/ASA) also recommends consideration of
cardiac screening for asymptomatic CHD based on a high-risk
Framingham Cardiac Risk Score (FCRS ≥20%).3,5-7
Investigating the presence of occult CHD among patients with
cerebrovascular disease may be clinically prudent, given that
CHD is a leading cause of morbidity and mortality in this
population.3,5-9 Determining whether patients with cerebrovas-
cular disease also have coronary atherosclerotic disease may have
important treatment implications,1,10,11 but a previous study
attempting to implement this guideline found that out-
patient providers did not pursue testing, given the lack of
evidence regarding whether such screening improved
poststroke outcomes.6
In the absence of a prospective study to ascertain whether
implementation of cardiac screening among patients
with a recent cerebrovascular event improves outcomes, we
used administrative data to determine whether (1) patients
with cerebrovascular disease routinely received cardiac stress
testing based on a high-risk FCRS and (2) screening for
asymptomatic CHD was associated with reduced 1-year all-
cause mortality. We also conducted chart reviews to identify
reasons why clinicians pursued cardiac stress testing.
Methods
Overview
This study was a secondary analysis of Veterans Health Admin-
istration (VA) administrative data, which were used to identify
Veterans (n = 11,306) with a primary diagnosis of acute ischemic
stroke or TIA who presented to a VA emergency department or
were admitted to a VA medical center in fiscal year (FY) 2011
(i.e., October 2010–September 2011). We excluded patients (n
= 6,097) based onmedical history ofCHD,myocardial infarction
(MI), angina/chest pain, or receipt of percutaneous transluminal
coronary angioplasty/percutaneous coronary intervention within
the previous 5 years (as identified by a combination of ICD-9 and
Common Procedural Terminology [CPT] codes); cardiac stress
test within the 18 months prior to their stroke/TIA event12,13;
death within the 90 days of discharge or discharge to hospice;
transfer to a non-VA acute care facility; or missing/unknown
race. These exclusions were not mutually exclusive. The final
analytic sample included 4,391 Veterans.
Standard protocol approvals, registrations,
and patient consents
Institutional review board approval was obtained for this
research.
Data
Data for demographic factors, medical comorbidities (e.g.,
CHD and MI), symptoms (e.g., angina/chest pain), and dis-
charge medications were obtained from existing VA data
sources: VHAAustin and fee-basis (which captures data related
to Veterans receiving care outside of VHA medical centers)
inpatient and outpatient data files in the 5 years pre cerebro-
vascular event (FY 2005–2012); a combination of ICD and
CPT codes were used to identify medical history variables.
Race/ethnicity data were collected from the Centers for
Medicare and Medicaid Services (CMS) vital status file and if
missing or unavailable, supplemented with data from the VA’s
Functional Status Outcomes Database and VHA Austin in-
patient and outpatient data files, if available. Only 1% of race
values were unknown and these patients were excluded from
the analyses because calculation of the FCRS requires race.
FCRS was calculated for each patient based on race- and sex-
specific pooled cohort equations that accounted for age, sex, race,
total and high-density lipoprotein (HDL) cholesterol, systolic
blood pressure (SBP; including treated or untreated), diabetes,
and current smoking status. The results are used to estimate an
individual’s 10-year risk of cardiovascular event, and can be re-
liably and accurately calculated from administrative data.14,15
SBP, total cholesterol, and HDL cholesterol values were based
on values at discharge from the index stroke or TIA event when
available; if no discharge measurement was available, the most
recent value prior to discharge was used (table e-1, links.lww.
com/CPJ/A25). Pharmacy Benefits Management data were
used to identify medications (e.g., antihypertensive medi-
cations), Corporate Data Warehouse data for blood pressure,
and laboratory data for total and HDL cholesterol.
Data for covariates related to indications other than a high
FCRS (e.g., troponin I > 0.1 mcg/L) were collected 180 days
prior to the cerebrovascular event and within 90 days after
the index. Angina/chest pain prior to the index event was an
exclusion to initial cohort construction; therefore, this
covariate reflects angina/chest pain that occurred within 90
days of the index cerebrovascular event.
The primary outcome of interest was receipt of any cardiac
stress testing, either pharmacologic (e.g., gated Persantine
study) or nonpharmacologic (e.g., treadmill stress test) among
high-risk patients within 90 days of hospital discharge. ICD-9
and CPT codes were used to identify cardiac stress testing
Cardiac stress testing for patientswith
cerebrovascular disease based on
a high-risk FCRS is not performed as
part of routine clinical care.
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Table 1 Patient characteristics at baseline, stratified by receipt of cardiac stress testa (n = 4,391)
Characteristic Stress test performed (n = 195) Stress test not performed (n = 4,196) p Value Total (n = 4,391)
Age, y, mean ± SD 66.1 ± 10.1 66.9 ± 11.6 0.25 66.9 ± 11.6
Sex: Male 97.9 95.5 0.11 95.7
Race: White/nonblack 85.1 72.8 0.0001 73.3
FCRS ≥20% 63.1 62.8 0.94 63.1
Index event
Stroke 68.2 69.9 0.61 69.8
TIA 31.8 30.1 0.61 30.2
Comorbidities
Hypertension 82.1 77.1 0.11 77.4
Diabetes 43.1 36.5 0.06 36.8
Hyperlipidemia 76.4 57.9 <0.0001 58.7
Current smoker 40.5 35.7 0.17 35.9
Atrial fibrillation 14.9 9.7 0.02 9.9
Congestive heart failure 15.9 7.0 <0.0001 7.4
Carotid artery disease 35.4 16.0 <0.0001 16.9
Carotid endarterectomy 13.8 3.4 <0.0001 3.9
Peripheral vascular disease 11.8 11.0 0.72 11.0
Dementia 2.6 5.2 0.10 5.1
Chronic obstructive pulmonary disease 21.5 18.0 0.21 18.2
Pneumonia 6.2 4.8 0.38 4.8
Cancerb 10.3 11.3 0.66 11.2
Chronic kidney disease 12.8 12.1 0.75 10.5
Charlson Comorbidity Index, mean (SD) 1.1 (1.6) 1.3 (1.8) 0.21 1.3 (1.8)
Indications for cardiac stress testing
Troponin I < 0.1 μg/L 8.7 4.8 0.02 5.0
Angina/chest pain 34.9 5.2 <0.0001 6.5
Lightheadedness 9.7 4.8 0.002 5.1
Shortness of breath 12.8 4.4 <0.001 4.8
Abnormal ECG 8.7 2.5 <0.001 2.8
Arrhythmiac 19.5 9.8 <0.0001 10.2
Aortic stenosis/regurgitation 3.6 3.0 0.65 3.0
Mitral stenosis/regurgitation 1.0 1.9 0.38 1.8
Medications
Statin use 76.4 71.3 0.12 71.6
Antihypertensive use
All BP medications 86.2 76.8 0.002 77.2
Beta-blocker 43.6 32.8 0.002 33.3
Diuretics 34.9 35.8 0.79 35.8
Continued
194 Neurology: Clinical Practice | Volume 8, Number 3 | June 2018 Neurology.org/CP
(table e-2, links.lww.com/CPJ/A25). Receipt of cardiac stress
testing was identified using VA administrative data, linked VA
CMS data, and VA fee-basis files; the combination of these data
sources allowed for identification of testing provided for
patients performed within and outside of the VA.
The secondary outcome of interest was all-cause 1-year
poststroke mortality, as measured from the VA’s Vital Status
File (VSF). The VA VSF contains dates of death from all VA
beneficiaries. Death information in the VA VSF originates
from a variety of VA and non-VA sources (e.g., CMS). Re-
search has shown that the VA VSF is relatively complete and
accurate when compared with information contained in the
National Death Index (NDI), with more than 98.3% of
deaths in the VA VSF confirmed with deaths in the NDI.16
Given that our study population was assembled based on
FY11 data, with mortality data being extracted at the end of
FY13, enough time had elapsed to capture mortality events
occurring 1 year after the index cerebrovascular event.
Data were also collected through retrospective chart review
on a sample of electronic medical records to determine
whether providers ordered stress testing based on a patient’s
high risk FCRS, and to collect other indications for (e.g.,
symptoms of chest pain or angina, preoperative evaluation
for carotid endarterectomy [CEA]) and results of stress
testing (e.g., positive dobutamine stress test in the area of left
anterior descending artery). Chart reviews were performed
by abstractors who were specially trained for the study.
Statistical analyses
We describe demographic and clinical characteristics of
participants based on receipt of cardiac stress testing and for
the overall study sample, using χ2 or Fisher exact tests for
categorical variables and Wilcoxon rank-sum or t tests for
continuous variables. We then compared these character-
istics among patients with FCRS ≥20%, also based on receipt
of stress testing. Two separate multivariable logistic re-
gression models were used to examine (1) whether cardiac
stress testing was performed more frequently for patients
with FCRS ≥20% compared with patients with FCRS <20%
and (2) the association of receipt of cardiac stress testing and
1-year all-cause mortality among the entire cohort. A
generalized linear mixed model with logit link was used to
model both outcomes. A random intercept of VA facility was
used to adjust for the correlation among patients within the
same facility. Covariates associated with outcomes in the
bivariate random effect model with p value <0.25, or clini-
cally important variables (e.g., FCRS), were included in the
multivariable models, and nonsignificant covariates were
dropped from the multivariable models one at a time. A ratio
of 10 outcome events per variable was maintained during
model construction.17,18 For each regression model, dis-
crimination (C statistics) was calculated to gauge model
performance. Because missing data were rare, no imputa-
tions were made. Given that the low 1-year mortality among
patients with FCRS ≥20% who received cardiac stress testing
precluded a meaningful analysis of a population for which
the AHA/ASA expert consensus guidelines recommend was
intended, we also calculated the sample size required to have
80% statistical power, with a 2-sided α of 0.05, to detect
a 20% difference in mortality among patients with a FCRS
≥20% who did and did not receive cardiac stress testing. All
statistical analyses used SAS version 9.2 (SAS Institute,
Cary, NC).
Data availability
Anonymized data not published within this article will be
made available by request from any qualified investigator if
approved by our Research Ethics Board. All analyses must be
conducted behind the VA firewall. Investigators interested in
working with the data should contact the authors.
Results
Themean age of the 4,391 patients in the studywas 66.9 years
(±SD 11.6) and 73.3% were not black; 3,067 had an ischemic
stroke (69.8%) and 1,324 had a TIA (30.2%) as their index
event (table 1). A high FCRS was calculated for 62.8%
(2,759/4,391) of patients.
Stress testing within 90 days of discharge occurred in 4.4% of all
patients (195/4,391); the rate of stress testing was nearly
identical among those with high and low/intermediate risk
FCRS: 4.5% (123/2,759) for high and 4.4% (72/1,632) for
Table 1 Patient characteristics at baseline, stratified by receipt of cardiac stress testa (n = 4,391) (continued)
Characteristic Stress test performed (n = 195) Stress test not performed (n = 4,196) p Value Total (n = 4,391)
ACEI/ARB 65.6 51.5 0.0001 52.1
Antiplatelet use 89.2 83.2 0.027 83.5
No. of pre-event NEXUS visits, mean (SD)d 4.1 (3.4) 3.8 (3.9) 0.051 3.8 (3.9)
Abbreviations: ACEI/ARB = angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; BP = blood pressure; FCRS = Framingham Cardiac Risk
Score.
a Percent shown unless otherwise indicated.
b Cancer includes: solid tumor (with and without metastatic disease), leukemia, lymphoma, and multiple myeloma.
c Arrhythmia (not including atrial fibrillation).
d NEXUS visits include primary care and selected specialty care visits.
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Table 2 Baseline characteristics among patients with high Framingham cardiac risk score (n = 2,759)a
Variable Stress test performed, % Stress test not performed, % p Value
Age, y, mean (SD) 70.1 (8.9) 72.0 (10.5) 0.03
Race: White/nonblack 83.7 73.1 0.009
Sex: Male 99.2 97.7 0.27
Index event
Stroke 72.4 71.3 0.80
TIA 27.6 28.7 0.80
Comorbidities
Hypertension 88.6 83.7 0.15
Diabetes 61.0 50.0 0.02
Hyperlipidemia 81.3 61.6 <0.0001
Current smoker 42.3 36.4 0.19
Atrial fibrillation 16.3 12.6 0.23
Congestive heart failure 17.1 8.5 0.001
Carotid artery disease 35.0 17.4 <0.0001
Carotid endarterectomy 14.6 3.5 <0.0001
Peripheral vascular disease 12.2 12.6 0.91
Dementia 4.1 7.2 0.18
Chronic obstructive pulmonary disease 22.8 18.9 0.28
Pneumonia 4.9 5.3 0.93
Cancerb 9.8 13.4 0.24
Chronic kidney disease 17.1 16.0 0.75
Charlson Comorbidity Index, mean (SD) 1.2 (1.6) 1.5 (1.9) 0.09
Indications for cardiac stress testing
Troponin I <0.1 μg/L 8.9 5.3 0.09
Angina/chest pain 34.1 4.7 <0.0001
Lightheadedness 8.9 4.9 0.05
Shortness of breath 13.8 5.0 <0.0001
Abnormal ECG 11.4 2.7 <0.0001
Arrhythmiac 18.7 10.7 0.006
Aortic stenosis/regurgitation 4.9 3.8 0.54
Mitral stenosis/regurgitation 0.8 2.2 0.31
Medications
Statin use 82.9 74.3 0.03
Antihypertensive use
All BP medications 89.4 85.1 0.19
Beta-blocker 48.0 37.6 0.02
Diuretics 39.0 40.1 0.81
Continued
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low/intermediate FCRS. Patients receiving stress testing
(comparedwith patients not receiving stress testing)weremore
likely to be not black with a history of hyperlipidemia, atrial
fibrillation, congestive heart failure (CHF), carotid artery dis-
ease, CEA, elevated troponin I during admission, angina,
lightheadedness, shortness of breath, abnormal ECG, and ar-
rhythmia (other than atrial fibrillation), and to be prescribed
antihypertensive and antiplatelet medications at discharge
(table 1). Similar reasons for obtaining screening occurred in
a sample restricted to high-risk patients (table 2). After
adjusting for FCRS and sociodemographic and baseline char-
acteristics, patients had a higher odds of receiving a cardiac
stress test if they were not black, male, with a history of hy-
perlipidemia, diabetes, CHF, carotid artery disease, CEA, an-
gina, lightheadedness, shortness of breath, abnormal ECG, or
arrhythmia (other than atrial fibrillation). FCRS was not as-
sociated with receipt of stress testing in unadjusted or adjusted
analyses (adjusted odds ratio [aOR] 0.77; confidence interval
[CI] 0.54–1.10; table 3).
Among the 4.4% (195/4,391) of patients receiving cardiac
stress testing within 90 days of discharge, 3.6% (7/195) were
dead at 1 year; 5.6% (234/4,196) of patients who did not
receive stress testing were dead at 1 year. Neither unadjusted
nor adjusted (aOR 0.59; 95% CI 0.26–1.30) analyses dem-
onstrated an association between cardiac stress testing and
mortality. Among the 62.8% (2,759/4,391) of patients with
a high FCRS, 6.8% (188/2,759) were dead at 1 year; 3.3%
(53/1,632) with a low/intermediate risk FCRS were dead at
1 year. High FCRS was associated with higher 1-year mor-
tality (aOR 1.48; 95% CI 1.06–2.07; p < 0.001; table 4).
In a subsample (n = 3,099) of patients who did not have reasons
to receive cardiac stress testing other than high FCRS (e.g.,
abnormal ECG), stress testing was not performed more com-
monly among patients with high FCRS compared to low/
intermediate FCRS (2.5% vs 2.4%; p = 0.833). In contrast,
patients who had other reasons for receiving cardiac stress
testing more commonly had stress testing performed compared
to those who did not have other reasons to receive stress testing
(9.13% vs 2.48%; p < 0.0001).
To detect a mortality difference among patients with FCRS
≥20% who did and did not receive cardiac stress testing, we
estimated (for 50% screening prevalence) that 2,178 patients
would be required in each group. In contrast, this analysis
included 195 patients who received stress testing and 4,196
who did not receive testing.
In charts available for review (n = 17), chest pain/angina and
preoperative/perioperative assessment for CEA/stent pro-
cedure or “other surgery” accounted for 53% (n = 9/17) of
the cardiac screening indications; none of these procedures
or surgeries was performed based on high-risk FCRS
(table e-3, links.lww.com/CPJ/A25).
Table 2 Baseline characteristics among patients with high Framingham cardiac risk score (n = 2,759)a (continued)
Variable Stress test performed, % Stress test not performed, % p Value
ACEI/ARB 74.0 57.6 0.0003
Antiplatelet use 88.6 85.9 0.39
No. of pre-event NEXUS visitsd 4.2 (3.3) 4.0 (4.0) 0.19
Abbreviations: ACEI/ARB = angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; BP = blood pressure; FCRS = Framingham Cardiac Risk
Score.
a Percent shown unless otherwise indicated.
b Cancer includes solid tumor (with and without metastatic disease), leukemia, lymphoma, and multiple myeloma.
c Arrhythmia (not including atrial fibrillation).
d NEXUS visits include primary care and selected specialty care visits.
Table 3 Association between Framingham cardiac risk
score and receipt of cardiac stress testing
adjusted for patient characteristics at baseline
(n = 4,391)
Effect aOR 95% CI p Value
FCRS ≥20% vs FCRS <20% 0.77 0.54–1.10 0.15
Race (white/nonblack) 1.70 1.09–2.65 0.02
Male vs female 3.39 1.07–10.75 0.04
Hyperlipidemia 1.79 1.25–2.58 0.002
Diabetes 1.73 1.20–2.49 0.004
Congestive heart failure 2.62 1.65–4.15 <0.0001
Carotid artery disease 1.77 1.19–2.65 0.006
Carotid endarterectomy 2.84 1.60–5.03 0.006
Lightheadedness 1.87 1.07–3.27 0.03
Angina/chest pain 9.49 6.60–13.63 <0.0001
Shortness of breath 1.95 1.16–3.26 0.02
Abnormal EGC 2.24 1.18–4.28 0.02
Arrhythmiaa 1.56 1.02–2.39 0.04
Charlson Comorbidity Index 0.87 0.78–0.96 0.009
Abbreviations: aOR = adjusted odds ratio; CI = confidence interval; FCRS =
Framingham Cardiac Risk Score.
a Arrhythmia (not including atrial fibrillation).
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Discussion
Cardiac stress testing for patients with cerebrovascular dis-
ease based on a high-risk FCRS is not performed as part of
routine clinical care. Given our limited ability tomodel 1-year
all-cause mortality among patients for whom the AHA/ASA
expert consensus guideline recommends consideration of
screening (i.e., FCRS ≥20%), we cannot comment on
whether routine screening for high-risk patients with cere-
brovascular disease should be performed from a mortality
perspective. When examining the association among all
patients with cerebrovascular disease irrespective of their
FCRS, we found no mortality benefit for cardiac screening.
We also identified important predictors of receiving cardiac
stress testing.
Although the FCRS was originally intended to prognosticate
10-year risk of CHD-related events, it has been used to predict
shorter-term outcomes among patients with cerebrovascular
disease.5,7 A high-risk FCRS has been shown to predict
a higher hazard of MI (adjusted hazard ratio 3.70; 95% CI
2.14–6.38) and MI or vascular death (adjusted hazard ratio
2.21; 95% CI 1.48–3.28) among noncardioembolic poststroke
patients.7 Our finding that high-risk FCRS was associated with
higher 1-year mortality among our cohort of stroke and TIA
patients is similar to another study demonstrating the associ-
ation between increasing FCRS and likelihood of death and
disability during an index admission with stroke.5
An important consideration regarding the implementation of
CHD screening based on high-risk FCRS is the prevalence of
CHD among asymptomatic patients. Prior studies have ex-
amined the prevalence of asymptomatic CHD in patients with
cerebrovascular disease, with an estimated 20%–40% having
silent cardiac ischemia as diagnosed by cardiac stress testing.19
When considering the prevalence of angiographically di-
agnosed CHD, 62% of patients with cerebrovascular disease
and without CHD had coronary artery plaques, whereas 26%
of patients had coronary artery stenosis ≥50%. These patients
had markedly increased risk of vascular events despite re-
ceiving best medical management for asymptomatic CHD.20
Noting the potential importance of CHD and CHD-related
events among patients with cerebrovascular disease, AHA/
ASA Scientific Statement expert consensus guidelines rec-
ommended that providers should consider evaluating for oc-
cult CHD for patients with FCRS ≥20%.3
A study examining the implementation of this recommen-
dation for poststroke CHD screening found that a minority
of eligible patients received testing.6 When testing was per-
formed, 14% of patients had a positive stress test, with these
patients going on to be prescribed β-blockers.6 While we
found that clinicians utilized cardiac stress testing for several
approved indications (e.g., chest pain/angina),21,22 our
results also demonstrate relative underuse of stress testing
among asymptomatic patients with cerebrovascular disease
and high-risk FCRS.
In recent years, ischemic stroke, and more specifically ath-
erosclerotic stroke, has appropriately been recognized as an
important cardiac risk equivalent, given the association be-
tween stroke and the approximate ≥20% absolute risk of fatal
Table 4 Unadjusted and adjusted associations between cardiac screening 1-year mortality
Effect Unadjusted OR (95% CI)a Model 1: adjusted OR (95% CI)b Model 2: adjusted OR (95% CI)c Model 3: adjusted OR (95% CI)d
Receipt of cardiac
screening
0.62 (0.28–1.35) 0.62 (0.28–1.34) 0.61 (0.28–1.32) 0.59 (0.26–1.30)
Not receiving
cardiac screening
Reference Reference Reference Reference
FCRS ≥20% — 2.18 (1.59–2.98) 2.18 (1.59–3.00) 1.48 (1.06–2.07)
FCRS <20% Reference Reference Reference Reference
Abbreviations: CI = confidence interval; FCRS = Framingham Cardiac Risk Score; OR = odds ratio.
a p Value: 0.22, C statistic: 0.70.
b Model 1: Adjusted for FCRS; an interaction between receipt of cardiac screening and FCRS was nonsignificant. C statistic: 0.70.
c Model 2: Adjusted for FCRS, sex, and race. C statistic: 0.68.
d Model 3: Adjusted for FCRS, atrial fibrillation, congestive heart failure, being a current smoker, chronic kidney disease, dementia, pneumonia, cancer,
Charlson Comorbidity Index, troponin I > 0.1 μg/L, and statin use. C statistic: 0.77.
Possible explanations for our
observed racial difference in cardiac
stress testing among patients with
a cerebrovascular event include race-
based differences in access to care,
perceptions of testing and
procedures, and socioeconomic
status.
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or nonfatal MI or sudden death.23 Another rationale for con-
sidering ischemic stroke as a cardiac equivalent has been to
promote the delivery of effective preventive strategies among
all cardiac risk equivalents.23 This becomes especially impor-
tant when considering that patients with cerebrovascular dis-
ease generally have poorer control of their vascular risk factors
than patients with other cardiac equivalents.14,24,25
A key finding of these analyses was the identification of
predictors of receiving cardiac stress testing. Not surprisingly,
patients with well-established reasons to receive cardiac
stress testing (e.g., angina/chest pain), conditions associated
with increased vascular risk (e.g., hyperlipidemia), and ca-
rotid artery disease, as another cardiac equivalent, had
a greater odds of receiving stress testing (tables 1 and 3).23
Although diabetes was associated with a higher odds of re-
ceiving cardiac screening in this cohort, a study conducted
among patients with diabetes suggests that cardiac screening
should not be pursued when the intent is to decrease cardiac
event rates.24 Outside of the cerebrovascular literature,
a lower burden of medical comorbidities was associated with
an increased likelihood of receiving stress testing.26 One
explanation for this finding is that patients with a greater
degree of comorbidity may be “too sick” or have medical
contraindications to undergo cardiac stress testing. We were
surprised to detect racial differences related to receiving
cardiac screening. Data from nonstroke populations indicate
that black patients with cardiac disease are less likely to re-
ceive revascularization procedures both within27 and outside
of the VA.28 Among Medicare beneficiaries, nonblack men
are more likely to receive cardiac screening then black men.29
Possible explanations for our observed racial difference in
cardiac stress testing among patients with a cerebrovascular
event include race-based differences in access to care, per-
ceptions of testing and procedures, and socioeconomic sta-
tus. As the VA is not a fee-for-service enterprise, the ability of
patients to pay for procedures is less likely to contribute to
the observed racial disparity.
The strengths of our study include the large sample size and
the ability to control for several important sociodemographic
and baseline medical and neurologic conditions. Further-
more, chart review data helped to further illuminate reasons
clinicians order cardiac stress testing for patients with cere-
brovascular disease. Limitations of our study are worth not-
ing. First, given that this is an observational study rather than
a randomized controlled trial, we can only comment on
associations rather than causation. Second, since few patients
died in our sample who had both a FCRS ≥20% and cardiac
screening, we were unable to adjust for other important
predictors of mortality and therefore were unable to assess
the association between cardiac screening and 1-year all-
cause mortality among high-risk patients with cerebrovas-
cular disease. As such, we were only able to examine a pos-
sible association between receiving CHD screening and
mortality among all patients, rather than the subset of
patients for which the consensus opinion was intended.
Future work should examine whether the association be-
tween receipt of cardiac stress testing for asymptomatic
CHD and mortality in an exclusively high-risk cerebrovas-
cular disease population for several treatment implications
related to vascular risk factor management. For example,
recent cerebrovascular prevention guidelines recommend
initiation of hydrochlorothiazide or angiotensin-converting
enzyme inhibitor rather than β-blocker.1 β-blockers may less
effectively prevent ischemic stroke in comparison to other
agents, whereas they are the cornerstone of CHD treat-
ment.11 Current CHD guidelines do not recommend the use
of the combination aspirin/extended release dipyridamole,10
whereas there is Class I/Level of Evidence B for its use in
stroke prevention.1 Third, we examined the relationship
between all-cause mortality and receipt of stress testing
rather than more cardiac-specific outcomes (e.g., coronary
revascularization). Fourth, we cannot identify stroke sub-
type. Cardiac stress tests are more likely to be abnormal
among patients with atherosclerotic-associated strokes
compared with nonatherosclerotic strokes (50% vs 23%; p =
0.04).30 Patients with cerebrovascular events secondary to
cardioembolic disease and those with carotid artery disease
have been found to be at high risk of having occult CHD3;
interestingly, etiologies leading to cardioembolic strokes and
carotid artery disease were more prevalent among those who
received cardiac screening. Finally, as our cohort comprises
predominantly male Veterans, these results may be less
generalizable to other populations.
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